Advanced search
Publication Cover
Cancer Biology & Therapy Volume 21, 2020 - Issue 11
Submit an article Journal homepage
742
Views
4
CrossRef citations to date
0
Altmetric
Research Paper

Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and in vivo tumor growth of triple-negative breast cancer

Ricardo E PerezDepartment of Cell and Molecular Medicine, Rush University Medical Center, Chicago, IL, USAView further author information
,
Sarah CalhounDepartment of Cell and Molecular Medicine, Rush University Medical Center, Chicago, IL, USAView further author information
,
Daeun ShimDepartment of Cell and Molecular Medicine, Rush University Medical Center, Chicago, IL, USAView further author information
,
Victor V. LevensonDepartment of Cell and Molecular Medicine, Rush University Medical Center, Chicago, IL, USAView further author information
,
Lei DuanDepartment of Cell and Molecular Medicine, Rush University Medical Center, Chicago, IL, USAView further author information
&
Carl G. MakiDepartment of Cell and Molecular Medicine, Rush University Medical Center, Chicago, IL, USACorrespondence[email protected]
View further author information
Pages 1033-1040 | Received 17 Apr 2020, Accepted 10 Sep 2020, Published online: 12 Oct 2020

References

  • Szeltner Z, Polgar L. Structure, function and biological relevance of prolyl oligopeptidase. Current Prot Pept Sci. 2008;9:96–107.
  • Myohanen TT, Pyykko E, Mannisto PT, Carpen O. Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors. J Histochem Cytochem. 2012;60:706–715.
  • Walter R, Shlank H, Glass JD, Schwartz IL, Kerenyi TD. Leucylglycinamide released from oxytocin by human uterine enzyme. Science. 1971;173:827–829.
  • Myohanen TT, Garcia-Horsman JA, Tenorio-Laranga J, Mannisto PT. Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity. J Histochem Cytochem. 2009;57:831–848.
  • Goossens F, De Meester I, Vanhoof G, Scharpe S. Distribution of prolyl oligopeptidase in human peripheral tissues and body fluids. Eur J Clin Chem Clin Biochem. 1996;34:17–22.
  • Larrinaga G, Perez I, Blanco L, Lopez JI, Andres L, Etxezarraga C, Santaolalla F, Zabala A, Varona A, Irazusta J. Increased prolyl endopeptidase activity in human neoplasia. Regul Pept. 2010;163:102–106.
  • Tanaka S, Suzuki K, Sakaguchi M. The prolyl oligopeptidase inhibitor SUAM-14746 attenuates the proliferation of human breast cancer cell lines in vitro. Breast Cancer. 2017;24:658–666.
  • Suzuki K, Sakaguchi M, Tanaka S, Yoshimoto T, Takaoka M. Prolyl oligopeptidase inhibition-induced growth arrest of human gastric cancer cells. Biochem Biophys Res Comm. 2014;443:91–96.
  • Sakaguchi M, Matsuda T, Matsumura E, Yoshimoto T, Takaoka M. Prolyl oligopeptidase participates in cell cycle progression in a human neuroblastoma cell line. Biochem Biophys Res Comm. 2011;409:693–698.
  • Jackson KW, Christiansen VJ, Yadav VR, Silasi-Mansat R, Lupu F, Awasthi V, Zhang RR, McKee PA. Suppression of tumor growth in mice by rationally designed pseudopeptide inhibitors of fibroblast activation protein and prolyl oligopeptidase. Neoplasia. 2015;17:43–54.
  • Duan L, Ying G, Danzer B, Perez RE, Shariat-Madar Z, Levenson VV, Maki CG. The prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT. J Biol Chem. 2014;289:21694–21705.
  • Nakajima T, Ono Y, Kato A, Maeda J, Ohe T. Y-29794–a non-peptide prolyl endopeptidase inhibitor that can penetrate into the brain. Neurosci Lett. 1992;141:156–160.
  • Reuveni H, Flashner-Abramson E, Steiner L, Makedonski K, Song R, Shir A, Herlyn M, Bar-Eli M, Levitzki A. Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res. 2013;73:4383–4394.
  • Metz HE, Houghton AM. Insulin receptor substrate regulation of phosphoinositide 3-kinase. Clin Cancer Res. 2011;17:206–211.
  • Manning BD, Toker A. AKT/PKB Signaling: navigating the Network. Cell. 2017;169:381–405.
  • Yoneyama Y, Inamitsu T, Chida K, Iemura SI, Natsume T, Maeda T, Hakuno F, Takahashi SI. Serine Phosphorylation by mTORC1 Promotes IRS-1 Degradation through SCFbeta-TRCP E3 Ubiquitin Ligase. iScience. 2018;5:1–18.
  • Haruta T, Uno T, Kawahara J, Takano A, Egawa K, Sharma PM, Olefsky JM, Kobayashi M. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Molec Endocrinol. 2000;14:783–794.
  • Waumans Y, Baerts L, Kehoe K, Lambeir AM, De Meester I. The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis. Frontiers Immunol. 2015;6:387.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.